Theragenics has acquired, among other things, the U.S. and Canadian customers of EZB, the U.S. and Canadian rights to the AnchorSeed, VariStrand and related seed products, and the rights to the SeedLock Needle product. These products will be added to Theragenics’ existing product portfolio. Theragenics will manufacture the products at its current facilities in Buford, Georgia.
“This transaction continues our long-standing commitment to prostate brachytherapy and the physicians and patients who depend on it,” said Frank J. Tarallo, CEO of Theragenics Corporation. “As a manufacturer and supplier in this market, our focus has always been on quality and service. Theragenics has a history of providing physicians with the tools necessary to achieve results for their patients. We welcome the EZB customers and look forward to working with their programs. This transaction enhances our capabilities and expands our product portfolio for brachytherapy.”
Dr. Edgar Löffler, managing director of EZB, said: “Theragenics has been recognized as a leader in prostate brachytherapy and has been a valued partner of EZB in the United States. I am confident that Theragenics will continue the quality and service to which the EZB customers and patients they serve have grown accustomed.”
Theragenics Corporation is a Buford, Ga.-based medical device company focusing on the cancer treatment and surgical products market. Theragenics’ brachytherapy business manufactures and sells products used primarily in the minimally invasive treatment of localized prostate cancer and breast cancer. The surgical products business manufactures and distributes wound closure, vascular access, and specialty needle products. The surgical segment serves a number of markets including interventional cardiology, interventional radiology, vascular surgery, orthopedics, plastic surgery, dental surgery, urology, veterinary medicine, pain management, endoscopy, and spinal surgery.